The study of dapagliflozin (sodium glucose cotransporter 2 inhibitor) to verify the efficacy of combination therapy in Japanese patients with type 2 diabetes

The study of dapagliflozin (sodium glucose cotransporter 2 inhibitor) to verify the efficacy of combination therapy in Japanese patients with type 2 diabetes - DISCOVERY study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015369

Enrollment

100

Registered

2014-10-08

Start date

2014-06-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Orally administration of 5 mg dapagliflozin once a day for 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age: >= 20 and <= 75 2) HbA1c: >= 7.0 and <= 10% 3) Change of HbA1c within 3 months prior to registration: <= +/-1%

Exclusion criteria

Exclusion criteria: 1) type 1 diabetes 2) BMI: >= 45 3) patients suspected of pregnancy or pregnant or nursing 4) diabetes insipidus 5) severe liver dysfunction (liver cirrhosis, viral hepatitis, AST: >= 3 times of upper limit) 6) moderate renal dysfunction (eGFR: < 45 ml/min/1.73m2) 7) heart disease (myocardial infarction, unstable angina) or stroke within 3 months 8) considered as inadequate by the investigator

Design outcomes

Primary

Measure	Time frame
Change and percent change in HbA1c from baseline to 6 months Adverse events	—

Countries

Japan

Contacts

Public ContactDAISUKE OGAWA

Okayama University Hospital nephrology, diabates and endocrinology

daiogawa@md.okayama-u.ac.jp086-235-7235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026